Brief: Urogen Pharma Announces License And Supply Agreement With Neopharm To Pursue Regulatory Approval And Commercialization For Jelmyto® In Israel
28/07/2021 21:02
July 28 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA ANNOUNCES LICENSE AND SUPPLY AGREEMENT WITH
NEOPHARM TO PURSUE REGULATORY APPROVAL AND COMMERCIALIZATION FOR
JELMYTO® IN ISRAEL
Source text for Eikon: ID:nBw6zYxJ8a
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors